Literature DB >> 32444495

Disruption of profilin1 function suppresses developmental and pathological retinal neovascularization.

David Gau1, Lucile Vignaud2, Abigail Allen1, Zhijian Guo3, Jose Sahel2,4, David Boone5, David Koes6, Xavier Guillonneau7, Partha Roy8,9.   

Abstract

Angiogenesis-mediated neovascularization in the eye is usually associated with visual complications. Pathological angiogenesis is particularly prominent in the retina in the settings of proliferative diabetic retinopathy, in which it can lead to permanent loss of vision. In this study, by bioinformatics analyses, we provide evidence for elevated expression of actin-binding protein PFN1 (profilin1) in the retinal vascular endothelial cells (VECs) of individuals with proliferative diabetic retinopathy, findings further supported by gene expression analyses for PFN1 in experimentally induced abnormal retinal neovascularization in an oxygen-induced retinopathy murine model. We observed that in a conditional knockout mouse model, postnatal deletion of the Pfn1 gene in VECs leads to defects in tip cell activity (marked by impaired filopodial protrusions) and reduced vascular sprouting, resulting in hypovascularization during developmental angiogenesis in the retina. Consistent with these findings, an investigative small molecule compound targeting the PFN1-actin interaction reduced random motility, proliferation, and cord morphogenesis of retinal VECs in vitro and experimentally induced abnormal retinal neovascularization in vivo In summary, these findings provide the first direct in vivo evidence that PFN1 is required for formation of actin-based protrusive structures and developmental angiogenesis in the retina. The proof of concept of susceptibility of abnormal angiogenesis to small molecule intervention of PFN1-actin interaction reported here lays a conceptual foundation for targeting PFN1 as a possible strategy in angiogenesis-dependent retinal diseases.
© 2020 Gau et al.

Entities:  

Keywords:  Profilin1 (PFN1); actin; angiogenesis; cytoskeleton; diabetic retinopathy; filopodia; oxygen-induced retinopathy (OIR); profilin; retina; tip cells; vascular endothelial cells (VECs); vascularization

Mesh:

Substances:

Year:  2020        PMID: 32444495      PMCID: PMC7363146          DOI: 10.1074/jbc.RA120.012613

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

Review 1.  The mouse retina as an angiogenesis model.

Authors:  Andreas Stahl; Kip M Connor; Przemyslaw Sapieha; Jing Chen; Roberta J Dennison; Nathan M Krah; Molly R Seaward; Keirnan L Willett; Christopher M Aderman; Karen I Guerin; Jing Hua; Chatarina Löfqvist; Ann Hellström; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06       Impact factor: 4.799

Review 2.  Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients.

Authors:  David M Brown; Carl D Regillo
Journal:  Am J Ophthalmol       Date:  2007-10       Impact factor: 5.258

3.  Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab.

Authors:  Maria Salling Eghøj; Torben Lykke Sørensen
Journal:  Br J Ophthalmol       Date:  2011-07-06       Impact factor: 4.638

Review 4.  Vitreous biomarkers in diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Annie K McAuley; Paul G Sanfilippo; Alex W Hewitt; Helena Liang; Ecosse Lamoureux; Jie Jin Wang; Paul P Connell
Journal:  J Diabetes Complications       Date:  2013-10-04       Impact factor: 2.852

5.  Profilin-1 mediates microvascular endothelial dysfunction in diabetic retinopathy through HIF-1α-dependent pathway.

Authors:  Hao Ding; Bin Chen; Qianyi Lu; Jian Wang
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

6.  Structure-based virtual screening identifies a small-molecule inhibitor of the profilin 1-actin interaction.

Authors:  David Gau; Taber Lewis; Lee McDermott; Peter Wipf; David Koes; Partha Roy
Journal:  J Biol Chem       Date:  2017-12-27       Impact factor: 5.157

7.  Profilin1 is required for glial cell adhesion and radial migration of cerebellar granule neurons.

Authors:  Jan A Kullmann; Alexander Neumeyer; Christine B Gurniak; Eckhard Friauf; Walter Witke; Marco B Rust
Journal:  EMBO Rep       Date:  2011-12-23       Impact factor: 8.807

Review 8.  RhoA/mDia-1/profilin-1 signaling targets microvascular endothelial dysfunction in diabetic retinopathy.

Authors:  Qianyi Lu; Li Lu; Wei Chen; Haibing Chen; Xun Xu; Zhi Zheng
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-03-20       Impact factor: 3.117

9.  Endothelial basement membrane limits tip cell formation by inducing Dll4/Notch signalling in vivo.

Authors:  Denise Stenzel; Claudio A Franco; Soline Estrach; Amel Mettouchi; Dominique Sauvaget; Ian Rosewell; Andreas Schertel; Hannah Armer; Anna Domogatskaya; Sergey Rodin; Karl Tryggvason; Lucy Collinson; Lydia Sorokin; Holger Gerhardt
Journal:  EMBO Rep       Date:  2011-10-28       Impact factor: 8.807

10.  The multifaceted role of profilin-1 in adipose tissue inflammation and glucose homeostasis.

Authors:  Munkyong Pae; Giulio R Romeo
Journal:  Adipocyte       Date:  2013-11-05       Impact factor: 4.534

View more
  3 in total

1.  Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells.

Authors:  Abigail Allen; David Gau; Paul Francoeur; Jordan Sturm; Yue Wang; Ryan Martin; Jodi Maranchie; Anette Duensing; Adam Kaczorowski; Stefan Duensing; Lily Wu; Michael T Lotze; David Koes; Walter J Storkus; Partha Roy
Journal:  J Biol Chem       Date:  2020-09-03       Impact factor: 5.157

2.  Inhibition of ocular neovascularization by novel anti-angiogenic compound.

Authors:  David Gau; Lucile Vignaud; Paul Francoeur; David Koes; Xavier Guillonneau; Partha Roy
Journal:  Exp Eye Res       Date:  2021-11-22       Impact factor: 3.467

Review 3.  The role of profilin-1 in cardiovascular diseases.

Authors:  Abigail Allen; David Gau; Partha Roy
Journal:  J Cell Sci       Date:  2021-05-07       Impact factor: 5.235

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.